Are you interested in optimising performance of your upstream biologics manufacturing? Cell retention/media perfusion devices increase the viable cell density of bioreactors and can be used to reduce the number or volume of seeding stages of the production bioreactor (1,2,3). Additionally, the production cycle can
A Case Study based on the Covid-19 vaccine being developed by the Jenner Institute, Oxford University. An affordable, global vaccine for Covid-19 is still seen as the best chance of protecting vulnerable people and populations at the same time as getting everyone back to normal
The biopharmaceutical industry is investigating various biologics as treatments for COVID-19. This blog looks at the scale of global manufacturing that may be required and the associated cost of goods of these drug products for COVID-19. Vaccine manufacturing will be discussed in a separate blog.
Biopharmaceutical manufacturing capacity, efficiency, flexibility and economics are all important outputs for organisations to optimize and continuously review. BioSolve Process is the biopharmaceutical industry’s most powerful software for bioprocess analysis. Due to the complexity of therapeutic manufacturing there are many variables contributing to the overall
As cell therapy processes mature and advance further beyond clinical trials, the shift to the manufacture and supply of affordable therapies will become more important. These therapies are expensive. High cost of goods (COGs) can be a cause of commercial failure with cell therapies, so
As we develop new processes and evaluate new technologies it is important to consider sustainability and the environmental impact and how this can be improved. It is an area that we have been actively considering since the early days of BioSolve Process; when the focus
World-class bioprocess modelling software developer unveils new customisable features for users. LONDON, 11 December 2019 – Biopharm Services, the bioprocess analysis software developer, today announced the release of the latest version of its flagship process analysis and economic modelling tool, BioSolve Process. BioSolve Process 8
The BioSolve User forum was held in the historic town of Leiden; we welcomed over 20 attendees. We met together for a in-depth review of new features, and to learn from and interact with other users in the expanding community. A major theme of the
1. General questions What is your name, organization name and position? Magnus Bergman, Senior research engineer at the R&D department at Cytiva Would you classify yourself as a beginner, intermediate user or power user of BioSolve Process? Intermediate or power user. Which version of BioSolve
This is the exact question we asked an audience in a session led by our Sales & Marketing Director Dr Yuki Abe, alongside GE Healthcare’s Jonathan Royce at our User Group Forum back in April 2018. By using the power of real time polling, we
